Abstract
To the Editor .— We read with interest the article by Contopoulos-Ioannidis et al in the July 2004 issue of Pediatrics .1 We welcome this collation of pediatric data on the efficacy and safety of extended-interval aminoglycoside dosing (EIAD), given the lack of clear consensus about whether the existing evidence justifies a change in standard practice.2 This meta-analysis of the available evidence demonstrates that efficacy, and probably nephrotoxicity, is at least equivalent between EIAD and multiple daily-dosing regimens. More importantly, however, it identifies gaps in our knowledge about (1) the incidence of ototoxicity, (2) the appropriate dose …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
